

TRADE SECRET

**Attachment No. 1 – Specification of the Product and the amount of  
the Limit UTIP  
to the Agreement on Limitation of Risks Related to Reimbursement of  
Medicinal Product  
No. 151/2019**

1. The Holder is placing the medicinal product specified below on the market in the Czech Republic:

SÚKL code	Name	Supplement of the name
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████
██████████	██████████	██████████

2. Proceedings in question has been initiated on ██████████ and is conducted by the Institute under case No. ██████████.
3. The Parties have agreed that the Limit UTIP for the Indicated Patient is set as ██████████ cycles with the medicinal product ██████████ in the indication according to the specification of the Product in the Section 1 of this Attachment.
4. With reference to Article IV. Section 2 of the Agreement the Parties have agreed that, in the event of a significant change in circumstances consisting in the change of prices and reimbursements of medical products containing active substance ██████████ and/or ██████████, the Parties will enter into joint negotiations on the amendment of the Agreement regarding the above agreed Limit UTIP.

In Prague on November 12, 2019

November 7, 2019

The Insurance Company:  
stamp and signature

The Holder:  
stamp and signature

\_\_\_\_\_  
Ing. David Šmehlík, MHA  
deputy director of Všeobecná zdravotní  
pojišťovna České republiky for healthcare

\_\_\_\_\_  
EGIS Praha, spol. s.r.o.  
MUDr. Vojtěch Mészáros, MBA, Director